leebs income performance letter posts
FeedPosted Mar 17th 2011 10:00AM by Steven Halpern (RSS feed)
Filed under: Cisco Systems (CSCO), Newsletters, Stocks to Buy
"We live in a networked world. And much of the backbone of that wired and increasingly wireless data/voice/video network is built on equipment produced by Cisco Systems (CSCO)," says Stephen Leeb.
The editor of Leeb's Income Performance Letter explains, "A colossus of the technology sector, it's the market leader in each of its business segments, including area networks, routing, switching, wireless LANs, web conferencing and digital video.
Continue reading Cisco Systems (CSCO): A 'Colossus' in Technology
Posted Oct 31st 2008 2:00PM by Steven Halpern (RSS feed)
Filed under: International Markets, Newsletters, Lockheed Martin (LMT), Stocks to Buy
"Investors should be well rewarded in the coming years by buying with major U.S. defense companies at current prices," says Gregory Dorsey.
The contributing editor to Stephen Leeb's Income Performance Letter explains, "The U.S. has more than doubled our sales of armaments to foreign nations over the past three years. And regardless of who wins the election, we expect this to continue."
"We're adding one for growth and income to our portfolio now. Lockheed Martin (NYSE: LMT) is a premier defense contractor. It's best known for its fighter jets.
"For example, Lockheed is now developing the F-35, also known as the Joint Strike Fighter, the replacement for the current generation of front-line fighters.
"But the company is actually engaged in four broad business areas, each of which should enjoy strong growth for years to come.
Continue reading Bet on defense: Leeb's look at Lockheed (LMT)
Posted Jun 12th 2008 11:44AM by Steven Halpern (RSS feed)
Filed under: Newsletters, Johnson and Johnson (JNJ), Stocks to Buy
"Our portfolio has been notably light on pharmaceuticals and consumer products; we're rectifying that by buying Johnson & Johnson (JNJ)," says Gregory Dorsey in Leeb's Income Performance Letter.
"Getting a handle on exactly what the 122 year-old company markets is no easy task, given the broad scope of its product line-up. And to say that J&J has been a resounding success on the corporate
stage would be an understatement.
"Through its more than 250 operating businesses, the parent company lays claim to being, among other things: the world's premier consumer health company, the largest medical devices and diagnostics company, the third-largest biologics company and the sixth-largest pharmaceuticals company.
"While acquisitions have played an important role in making the company what it is today, J&J has also achieved these milestones through internal growth. It boasts 75 consecutive years of rising sales.
Continue reading Johnson & Johnson (JNJ): A 'triple-A' rated play